About Actuate Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://actuatetherapeutics.com/
Frequently Asked Questions
What is the 52-week range for ACTU?
The 52-week high is $8.49 and the 52-week low is $0.6042.
What is the P/E ratio for ACTU?
The P/E ratio data is currently unavailable.
What is the dividend yield for ACTU?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -346.18%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 17.95.
Analyst Recommendation Trends
Wall Street analyst consensus for ACTU over the last few months:
Latest ACTU News
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS) shares moved
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-market session. The market value of their outstanding shares is at $7.4 million. Firefly Neuroscience (NASDAQ:AIFF) shares
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one mee
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
Independent studies conducted at Northwestern University and Mayo Clinic demonstrate synergistic activity of elraglusib in combination with RAS-targeted agents across multiple murine and human pancreatic cancer modelsData further support the potential for combination therapy strategies across other RAS-driven cancers Additional studies are ongoing with results to be presented at upcoming medical conferences CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, I
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-14 | SCHMITT DANIEL M | -272,056 | - | - |
| 2026-08-14 | SCHMITT DANIEL M | -120,521 | $1.01 | $121,726 |
| 2026-08-14 | SCHMITT DANIEL M | +272,056 | - | - |
| 2026-05-21 | Zabrowski Dan | +15,000 | - | - |
| 2026-05-21 | Sawhney Roger | +15,000 | - | - |
| 2026-05-21 | Keyes Jason A | +15,000 | - | - |
| 2026-05-21 | Huber Martin H. Jr. | +15,000 | - | - |
| 2026-05-21 | Fletcher Aaron G.L. | +15,000 | - | - |
| 2026-05-21 | RONNEBERG AMY L | +15,000 | - | - |
| 2026-05-21 | THOMSON TODD S | +15,000 | - | - |
| 2026-04-01 | Mazar Andrew Paul | +105,000 | - | - |
| 2026-04-01 | SCHMITT DANIEL M | +237,000 | - | - |
| 2026-04-01 | LYTLE PAUL J | +105,000 | - | - |
| 2026-02-13 | SCHMITT DANIEL M | -272,055 | - | - |
| 2026-02-13 | SCHMITT DANIEL M | -121,874 | $4.33 | $527,714 |
| 2026-02-13 | SCHMITT DANIEL M | +272,055 | - | - |
| 2026-01-05 | THOMSON TODD S | -280,000 | $5.8 | $1,624,000 |